NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2- Breast Cancer - PubMed
7 days ago
- #NK cells
- #Breast cancer
- #Immunotherapy
- Immunotherapy has limited efficacy in HR+/HER2- breast cancer.
- Activated NK cells correlate with better anti-PD-(L)1 responses in HR+/HER2- breast cancer.
- Preclinical models show immunotherapy enhances NK cell cytotoxicity and immunomodulatory functions, reducing tumor growth.
- Platinum drugs enhance NK cell cytotoxicity, possibly via the NF-κB pathway, synergizing with immunotherapy.
- Clinical cohort analysis reveals increased activated NK cells in tumors after platinum-based chemotherapy.
- The study highlights NK cells' role in immunotherapy response and platinum's potential to boost efficacy.